To investigate the role of IL-17 in the overproduction of autoantibodies and IL-6 overexpression by peripheral blood mononuclear cells (PBMC) of lupus nephritis (LN) patients Methods Fifteen consecutively hospitaliz...To investigate the role of IL-17 in the overproduction of autoantibodies and IL-6 overexpression by peripheral blood mononuclear cells (PBMC) of lupus nephritis (LN) patients Methods Fifteen consecutively hospitalized LN patients were selected as subjects and 15 healthy adults as normal controls PBMC were obtained by Ficoll density gradient centrifugation IgG, anti-dsDNA antibody and IL-6 protein levels were assessed using enzyme-linked immunosorbent assays (ELISA) on the supernatant of cul tured PBMC of LN patients or normal controls IL-6 mRNA levels in PBMC were measured using reverse transcription-polymerase chain reaction (RT-PCR) Results In medium culture, IgG, anti-dsDNA and IL-6 protein levels of the supernatant of PBMC from LN patients were significantly higher than those from normal controls (1492 1±73 2 ng/ml vs 636 7±51 9 ng/ml for IgG, 306 6±53 7 IU/ml vs 95 8±11 6 IU/ml for anti-dsDNA and 50 92±15 92 ng/ml vs 1 77±0 73 ng/ml for IL-6, all P<0 001) In LN patients, IgG, anti-dsDNA and IL-6 protein levels were higher in the supernatants of PBMC in the IL-17-stimulated culture than the medium culture, but in normal controls, only the IL-6 protein levels were significantly higher The increase in IgG, anti-dsDNA and IL-6 protein levels induced by IL-17 was dose-dependent and could be completely blocked by IL-17 monoclonal antibody mIgG 28 and partially blocked by dexamethasone Similarly, IL-6 mRNA overexpression of PBMC in LN patients or normal controls induced by IL-17 was both dose- and time-dependent During medium culture, IL-6 mRNA levels in LN patients were significantly higher than those in normal controls (1 80±0 11 vs 0 36±0 07) During stimulation with IL-17, IL-6 mRNA levels in LN patients were higher than those in normal controls (3 21±0 24 vs 1 30±0 14, P<0 05) and also significantly higher when comparing the stimulated culture with the medium culture either in LN patients or normal control Conclusions IL-17 may play an important role展开更多
目的观察匹多莫德联合氨溴特罗口服液治疗小儿急性支气管炎的临床疗效。方法选取2015年1月—2016年1月三门峡市中心医院收治的急性支气管炎患儿82例,随机分为对照组和治疗组,每组各41例。对照组口服氨溴特罗口服液,未满8个月,2.5 m L/...目的观察匹多莫德联合氨溴特罗口服液治疗小儿急性支气管炎的临床疗效。方法选取2015年1月—2016年1月三门峡市中心医院收治的急性支气管炎患儿82例,随机分为对照组和治疗组,每组各41例。对照组口服氨溴特罗口服液,未满8个月,2.5 m L/次;8个月~1岁,5 m L/次;2~3岁,7.5 m L/次;4~5岁,10 m L/次;6~12岁,15 m L/次,均为2次/d;治疗组在对照组的基础上口服匹多莫德分散片,0.4 g/次,2次/d。两组患儿均连续治疗7 d。比较两组患者临床疗效、临床症状体征消失时间,对比两组治疗前后Ig G、Ig A、Ig M指标水平。结果治疗后,对照组和治疗组的总有效率分别为92.68%和97.56%,两组总有效率比较差异具有统计学意义(P<0.05)。与对照组相比,治疗后治疗组患儿咳嗽及肺部啰音消失的更快,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患儿Ig G、Ig M水平明显升高,治疗组患儿Ig A水平比治疗前明显升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗后治疗组患儿Ig G、Ig A、Ig M水平明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论匹多莫德联合氨溴特罗口服液治疗小儿急性支气管炎具有良好的临床疗效,症状体征改善明显,具有一定的临床推广应用价值。展开更多
Hepatitis B virus （HBV） infection occurs primarily in hepatocytes in the liver with release of infectious virions and non-infectious empty surface antigen particles into the bloodstream. HBV replication is non-cytop...Hepatitis B virus （HBV） infection occurs primarily in hepatocytes in the liver with release of infectious virions and non-infectious empty surface antigen particles into the bloodstream. HBV replication is non-cytopathic. Transient infections run a course of several months, and chronic infections are often life-long. Chronic infections can lead to liver failure with cirrhosis and hepatocellniar carcinoma. It is generally accepted that neutralizing anti-HBs antibodies plays a key role in recovery from HBV infection by containing the spread of infection in the infected host and facilitating the removal and destruction of viral particles. However, the immune response initiated by the T-cell response to viral antigens is also important for viral clearance and disease pathogenesis in HBV infection. The three structural forms of the viral proteins, the HBsAg, the particulate HBcAg, and the nonparticulate HBeAg, may preferentially elicit different Th cell subsets. The different IgG subclass profiles of anti-HBs, anti-HBc, and anti-HBe in different HBV infection status were revealed. Moreover, the different IgG subclass profiles in chronic carriers did not change with different ALT and AST levels and may reflect the difference between stimulating antigens, immune response, and the stages of viral disease and provide the basis for the use of vaccines and prophylactic treatments for individuals at high risk of human HBV infection. This review elucidates the detailed understanding of the immune responses induced during transient and persistent infection, and the development of immunotherapy and immunodiagnosis in patients with HBV infection, and possible means of reducing the liver damage.展开更多
目的观察穴位贴敷联合健脾益气汤治疗小儿迁延性及慢性腹泻(persistent and chronic diarrheal disease,PCDD)脾胃虚弱证的临床疗效。方法选取PCDD脾胃虚弱证患儿78例,随机分为观察组和对照组,每组39例。两组患儿均继续饮食,但暂时停止...目的观察穴位贴敷联合健脾益气汤治疗小儿迁延性及慢性腹泻(persistent and chronic diarrheal disease,PCDD)脾胃虚弱证的临床疗效。方法选取PCDD脾胃虚弱证患儿78例,随机分为观察组和对照组,每组39例。两组患儿均继续饮食,但暂时停止添加新辅食,对照组采用蒙脱石散和双歧杆菌乳杆菌三联活菌片治疗,观察组采用穴位贴敷联合健脾益气汤治疗,两组均治疗28 d。比较两组患儿的临床疗效和不良反应情况;观察治疗前后两组患儿的血清特异性抗体IgA、IgG水平和中医证候积分变化。结果观察组总有效率为94.87%,高于对照组的76.92%(P<0.05);两组患儿血清IgA、IgG水平均较治疗前升高(P<0.05或P<0.01),且观察组高于对照组(P<0.05);两组患儿中医证候积分各个项目均较治疗前降低(P<0.05或P<0.01),且观察组均低于对照组(P<0.05)。结论穴位贴敷联合健脾益气汤治疗小儿PCDD脾胃虚弱证临床疗效显著,能明显提高血清特异性抗体IgA、IgG的水平,降低中医证候积分,值得临床推广应用。展开更多
基金Thisstudywassuportedfromgrantsfor211keyprojectsofSunYatSenUniversityofMedicalSciences (No .981 51 7)
文摘To investigate the role of IL-17 in the overproduction of autoantibodies and IL-6 overexpression by peripheral blood mononuclear cells (PBMC) of lupus nephritis (LN) patients Methods Fifteen consecutively hospitalized LN patients were selected as subjects and 15 healthy adults as normal controls PBMC were obtained by Ficoll density gradient centrifugation IgG, anti-dsDNA antibody and IL-6 protein levels were assessed using enzyme-linked immunosorbent assays (ELISA) on the supernatant of cul tured PBMC of LN patients or normal controls IL-6 mRNA levels in PBMC were measured using reverse transcription-polymerase chain reaction (RT-PCR) Results In medium culture, IgG, anti-dsDNA and IL-6 protein levels of the supernatant of PBMC from LN patients were significantly higher than those from normal controls (1492 1±73 2 ng/ml vs 636 7±51 9 ng/ml for IgG, 306 6±53 7 IU/ml vs 95 8±11 6 IU/ml for anti-dsDNA and 50 92±15 92 ng/ml vs 1 77±0 73 ng/ml for IL-6, all P<0 001) In LN patients, IgG, anti-dsDNA and IL-6 protein levels were higher in the supernatants of PBMC in the IL-17-stimulated culture than the medium culture, but in normal controls, only the IL-6 protein levels were significantly higher The increase in IgG, anti-dsDNA and IL-6 protein levels induced by IL-17 was dose-dependent and could be completely blocked by IL-17 monoclonal antibody mIgG 28 and partially blocked by dexamethasone Similarly, IL-6 mRNA overexpression of PBMC in LN patients or normal controls induced by IL-17 was both dose- and time-dependent During medium culture, IL-6 mRNA levels in LN patients were significantly higher than those in normal controls (1 80±0 11 vs 0 36±0 07) During stimulation with IL-17, IL-6 mRNA levels in LN patients were higher than those in normal controls (3 21±0 24 vs 1 30±0 14, P<0 05) and also significantly higher when comparing the stimulated culture with the medium culture either in LN patients or normal control Conclusions IL-17 may play an important role
文摘目的观察匹多莫德联合氨溴特罗口服液治疗小儿急性支气管炎的临床疗效。方法选取2015年1月—2016年1月三门峡市中心医院收治的急性支气管炎患儿82例,随机分为对照组和治疗组,每组各41例。对照组口服氨溴特罗口服液,未满8个月,2.5 m L/次;8个月~1岁,5 m L/次;2~3岁,7.5 m L/次;4~5岁,10 m L/次;6~12岁,15 m L/次,均为2次/d;治疗组在对照组的基础上口服匹多莫德分散片,0.4 g/次,2次/d。两组患儿均连续治疗7 d。比较两组患者临床疗效、临床症状体征消失时间,对比两组治疗前后Ig G、Ig A、Ig M指标水平。结果治疗后,对照组和治疗组的总有效率分别为92.68%和97.56%,两组总有效率比较差异具有统计学意义(P<0.05)。与对照组相比,治疗后治疗组患儿咳嗽及肺部啰音消失的更快,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患儿Ig G、Ig M水平明显升高,治疗组患儿Ig A水平比治疗前明显升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗后治疗组患儿Ig G、Ig A、Ig M水平明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论匹多莫德联合氨溴特罗口服液治疗小儿急性支气管炎具有良好的临床疗效,症状体征改善明显,具有一定的临床推广应用价值。
文摘Hepatitis B virus （HBV） infection occurs primarily in hepatocytes in the liver with release of infectious virions and non-infectious empty surface antigen particles into the bloodstream. HBV replication is non-cytopathic. Transient infections run a course of several months, and chronic infections are often life-long. Chronic infections can lead to liver failure with cirrhosis and hepatocellniar carcinoma. It is generally accepted that neutralizing anti-HBs antibodies plays a key role in recovery from HBV infection by containing the spread of infection in the infected host and facilitating the removal and destruction of viral particles. However, the immune response initiated by the T-cell response to viral antigens is also important for viral clearance and disease pathogenesis in HBV infection. The three structural forms of the viral proteins, the HBsAg, the particulate HBcAg, and the nonparticulate HBeAg, may preferentially elicit different Th cell subsets. The different IgG subclass profiles of anti-HBs, anti-HBc, and anti-HBe in different HBV infection status were revealed. Moreover, the different IgG subclass profiles in chronic carriers did not change with different ALT and AST levels and may reflect the difference between stimulating antigens, immune response, and the stages of viral disease and provide the basis for the use of vaccines and prophylactic treatments for individuals at high risk of human HBV infection. This review elucidates the detailed understanding of the immune responses induced during transient and persistent infection, and the development of immunotherapy and immunodiagnosis in patients with HBV infection, and possible means of reducing the liver damage.
